Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG505 SOSIP GT1.1 gp140 is an experimental HIV-1 vaccine candidate designed as a soluble, cleavage-competent trimeric envelope glycoprotein (gp140) based on the HIV-1 strain BG505 and engineered for germline-targeting to elicit broadly neutralizing antibody (bnAb) precursors against conserved epitopes of the virus[3][4][6]. The vaccine is administered intramuscularly and formulated with an adjuvant to enhance immune response[3][5]. It aims to induce B cell responses capable of maturing into protective bnAbs by targeting the CD4 binding site (CD4bs) and other conserved regions on the HIV envelope protein[4][6]. The immunogen was developed using structure-based design approaches to optimize its ability to engage diverse naive B cell receptors relevant for bnAb development[4][6]. Primary indication is prevention of HIV infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BG505 SOSIP GT1.1 gp140.